GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Total Receivables

Adagene (FRA:978) Total Receivables : €0.03 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Total Receivables?

Adagene's Total Receivables for the quarter that ended in Jun. 2024 was €0.03 Mil.


Adagene Total Receivables Historical Data

The historical data trend for Adagene's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Total Receivables Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial 1.93 0.11 6.64 0.58 0.20

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.77 0.58 0.36 0.20 0.03

Adagene Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Adagene Total Receivables Related Terms

Thank you for viewing the detailed overview of Adagene's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Adagene Business Description

Traded in Other Exchanges
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Adagene Headlines

No Headlines